Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pergamum has dosed first patient in a randomized Phase II study of DPK-060 for the treatment of patients with external otitis (swimmers ear).
Subscribe to our email newsletter
The objectives of double-blinded, randomized trial, are to assess the efficacy, local tolerability and safety of DPK-060 ear drops in infections caused by bacterial or fungal pathogens.
The placebo-controlled, multi-center trial is expected to enroll approximately 70 patients.
DPK-060 is a novel anti-microbial peptide which is structurally derived from the endogenous human protein kininogen.
Pergamum CEO Jonas Ekblom said they can avoid rapidly increasing global prevalence of antibiotics resistance that limits the therapeutic value of conventional products, with DPK-060 .